Journal
LABORATORY INVESTIGATION
Volume 99, Issue 11, Pages 1689-1701Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41374-019-0276-z
Keywords
-
Categories
Funding
- National Health and Medical Research Council (NHMRC) of Australia [APP1046647, 1141235]
- Australian Government Research Training Program Scholarship
- National Health and Medical Research Council of Australia [1141235] Funding Source: NHMRC
Ask authors/readers for more resources
Transforming growth factor beta (TGF-beta) is the key cytokine involved in causing fibrosis through cross-talk with major profibrotic pathways. However, inhibition of TGF-beta to prevent fibrosis would also abrogate its anti-inflammatory and wound-healing effects. beta-catenin is a common co-factor in most TGF-beta signaling pathways. beta-catenin binds to T-cell factor (TCF) to activate profibrotic genes and binds to Forkhead box O (Foxo) to promote cell survival under oxidative stress. Using a proximity ligation assay in human kidney biopsies, we found that beta-catenin/Foxo interactions were higher in kidney with little fibrosis, whereas beta-catenin/TCF interactions were upregulated in the kidney of patients with fibrosis. We hypothesised that beta-catenin/Foxo is protective against kidney fibrosis. We found that Foxo1 protected against rhTGF-beta 1-induced profibrotic protein expression using a CRISPR/cas9 knockout of Foxo1 or TCF1 in murine kidney tubular epithelial C1.1 cells. Co-administration of TGF-beta with a small molecule inhibitor of beta-catenin/TCF (ICG-001), protected against kidney fibrosis in unilateral ureteral obstruction. Collectively, our human, animal and in vitro findings suggest beta-catenin/Foxo as a therapeutic target in kidney fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available